BioAge Labs (NASDAQ:BIOA) Shares Down 6% - Here's What Happened

Key Points

• BioAge Labs shares fell about 6% on Friday to roughly $16.72, with mid-day volume around 78,900 shares — an ~89% drop versus its average daily volume.
• Analyst sentiment has turned generally positive: the consensus rating is Moderate Buy with a $46.25 average price target after several upgrades (Citigroup $52, Oppenheimer $60, Piper Sandler overweight), though one firm (Weiss) remains a sell.
• Significant insider selling has occurred — CEO Kristen Fortney sold 233,107 shares in January, and insiders disposed of 267,540 shares (~$4.9M) in the last 90 days, while insiders still own 20.82% of the company.

BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report)'s stock price was down 6% during trading on Friday . The stock traded as low as $16.74 and last traded at $16.7160. Approximately 78,899 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 705,451 shares. The stock had previously closed at $17.79.

Analyst Ratings Changes

Several equities analysts recently commented on BIOA shares. Wall Street Zen raised BioAge Labs from a "sell" rating to a "hold" rating in a report on Tuesday, February 3rd. Piper Sandler initiated coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They issued an "overweight" rating for the company. Citigroup upped their price objective on shares of BioAge Labs from $15.00 to $52.00 and gave the company a "buy" rating in a research note on Tuesday, March 10th. Oppenheimer initiated coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They issued an "outperform" rating and a $60.00 price objective for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

BioAge Labs Price Performance

The firm has a market cap of $726.06 million, a price-to-earnings ratio of -7.30 and a beta of 1.80. The firm's 50 day moving average price is $19.51 and its two-hundred day moving average price is $13.75.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its earnings results on Tuesday, March 24th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.11. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%. The business had revenue of $3.08 million during the quarter.

Insider Activity

In other news, CEO Kristen Fortney sold 233,107 shares of the company's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the transaction, the chief executive officer owned 976,949 shares of the company's stock, valued at $17,702,315.88. This represents a 19.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul D. Rubin sold 7,433 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.75, for a total transaction of $139,368.75. The SEC filing for this sale provides additional information. Insiders sold a total of 267,540 shares of company stock valued at $4,895,168 in the last 90 days. 20.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioAge Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIOA. Vanguard Group Inc. increased its position in BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock worth $9,709,000 after purchasing an additional 93,694 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs during the 4th quarter valued at $13,892,000. Geode Capital Management LLC lifted its holdings in shares of BioAge Labs by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company's stock valued at $7,826,000 after acquiring an additional 28,646 shares in the last quarter. State Street Corp lifted its holdings in shares of BioAge Labs by 113.4% during the 4th quarter. State Street Corp now owns 422,846 shares of the company's stock valued at $5,594,000 after acquiring an additional 224,735 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of BioAge Labs during the 4th quarter valued at $5,406,000.

About BioAge Labs

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.